Surmodics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Surmodics is gedaald met een gemiddeld jaarlijks percentage van -35.1%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 12%. De inkomsten zijn groeide met een gemiddeld percentage van 6.6% per jaar.

Belangrijke informatie

-35.1%

Groei van de winst

-35.4%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	6.6%
Rendement op eigen vermogen	-9.7%
Nettomarge	-9.2%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Jun 06

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04

Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Dec 24

Opbrengsten en kosten

Hoe Surmodics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:SRDX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	126	-12	53	0
30 Jun 24	121	-1	55	47
31 Mar 24	143	14	51	47
31 Dec 23	138	6	51	43
30 Sep 23	133	-2	52	47
30 Jun 23	131	-23	53	51
31 Mar 23	103	-36	53	51
31 Dec 22	102	-32	51	63
30 Sep 22	100	-27	47	51
30 Jun 22	98	-13	42	0
31 Mar 22	97	-10	37	0
31 Dec 21	106	2	34	0
30 Sep 21	105	4	32	49
30 Jun 21	104	2	30	0
31 Mar 21	107	7	30	0
31 Dec 20	95	1	28	0
30 Sep 20	95	1	28	0
30 Jun 20	103	8	28	0
31 Mar 20	101	7	27	0
31 Dec 19	100	6	26	0
30 Sep 19	100	8	25	0
30 Jun 19	92	2	24	0
31 Mar 19	90	-2	23	0
31 Dec 18	87	-2	24	0
30 Sep 18	81	-4	23	0
30 Jun 18	78	-2	22	0
31 Mar 18	74	1	22	0
31 Dec 17	72	0	21	0
30 Sep 17	73	4	20	0
30 Jun 17	71	6	20	0
31 Mar 17	73	9	19	0
31 Dec 16	73	10	19	0
30 Sep 16	71	10	18	0
30 Jun 16	71	9	17	0
31 Mar 16	67	9	16	0
31 Dec 15	64	11	15	0
30 Sep 15	62	12	13	0
30 Jun 15	60	13	15	0
31 Mar 15	59	13	15	0
31 Dec 14	58	12	15	0
30 Sep 14	57	12	15	0
30 Jun 14	56	13	15	0
31 Mar 14	56	13	16	0
31 Dec 13	56	14	15	0

Kwaliteitswinsten: SRDX is momenteel verliesgevend.

Groeiende winstmarge: SRDX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: SRDX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 35.1% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SRDX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SRDX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 10.4% ).

Rendement op eigen vermogen

Hoge ROE: SRDX heeft een negatief Return on Equity ( -9.71% ), omdat het momenteel verliesgevend is.

Surmodics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023)

Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 26% to US$43.00

Insufficient new directors

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce Thrombectomy System

Surmodics Receives FDA 510(k) Clearance for Pounce XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

Surmodics, Inc. Suspends Earnings Guidance for the Fiscal 2024

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Price target decreased by 10% to US$52.33

GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. (NasdaqGS:SRDX) for approximately $620 million.

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 24%

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024

New major risk - Revenue and earnings growth

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023)

Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System

Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Surmodics, Inc., Annual General Meeting, Feb 08, 2024

Insider exercised options and sold US$107k worth of stock

Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Surmodics, Inc. Announces Swing Trial 24-Month Data to Be Presented At Veith Symposium on November 15

Surmodics, Inc. Announces Launch of Preside Medical Device Coating Technology, Providing Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics, Inc. to Report Q4, 2023 Results on Nov 08, 2023

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Consensus revenue estimates increase by 12%

Price target increased by 8.7% to US$59.50

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q3, 2023 Results on Aug 02, 2023

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Surmodics, Inc.(NasdaqGS:SRDX) dropped from Russell 2000 Growth-Defensive Index

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Consensus revenue estimates increase by 11%

Surmodics, Inc. Receives FDA Approval for the SurVeil Drug-Coated Balloon

Surmodics Receives FDA 510(k) Clearance for Pounce LP Thrombectomy System

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Consensus EPS estimates upgraded to US$2.14 loss

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics, Inc. to Report Q1, 2023 Results on Feb 06, 2023

Consensus EPS estimates fall by 20%

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated Balloon

Price target decreased to US$61.00

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options and sold US$64k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Surmodics, Inc. Announces 24-Month Data from Its Transcend Clinical Trial At the Vascular InterVentional Advances

Surmodics, Inc. to Report Q4, 2022 Results on Nov 09, 2022

Surmodics, Inc. Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

Surmodics gets additional $125M in credit facility

Surmodics, Inc. Announces 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surmodics, Inc. Updates Earnings Guidance for the Fiscal Year 2022

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M